An Open Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a multicenter, single-arm, open-label study. Patients with Paroxysmal Nocturnal Hemoglobinuria who had previously received and completed the HRS-5965 study well included. All eligible subjects received HRS-5965 tablets or capsules until the end of treatment in this study.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 1\. Patients who have previously received and completed HRS-5965 study treatment, and are judged by the investigator to have treatment benefit and may benefit from continued treatment of HRS-5965 and patients in the control group of who received eculizumab treatment.
Locations
Other Locations
China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITING
Beijing
The Blood Disease Hospital of the Chinese Academy of Medical Sciences
RECRUITING
Tianjin
Contact Information
Primary
Sheng Qi
sheng.qi@hengrui.com
0518-82342973
Backup
Bin Hu
bin.hu5@hengrui.com
+86 18210289829
Time Frame
Start Date: 2024-02-06
Estimated Completion Date: 2027-12
Participants
Target number of participants: 120
Treatments
Experimental: HRS-5965 Group
Related Therapeutic Areas
Sponsors
Leads: Chengdu Suncadia Medicine Co., Ltd.